Accelerating Drug Development through Adaptive Design with SVP Global Development at Amgen
To Be Announced
This event starts on at
Please join YJP and, Elliott Levy, M.D., Senior Vice President, R&D Strategy and Operations at Amgen on January 26th at 5:30pm ET as we discuss accelerating Drug Development through Adaptive Design.
Through this mentorship initiative, young professionals will have the opportunity to explore innovative strategies to set your career goals for 2021. Our virtual community will have the opportunity to partake in an intimate and candid discussion with a Q&A session.
For questions about the event: please email email@example.com
*YJP has a non-solicitation policy covering all of our conferences and events. In order to provide a distraction-free environment for our mentors, sponsors, attendees, and employees, we do not allow solicitation at our events by attendees or unauthorized parties without the express written permission or consent from YJP.
Elliott M. Levy, M.D., is senior vice president, R&D Strategy and Operations, responsible for delivering the operational and transformational capabilities essential to executing Amgen’s R&D strategy. Levy joined Amgen in 2014 and was senior vice president, Global Development, responsible for the clinical
development of Amgen’s pipeline.
Before joining Amgen, Levy served as senior vice president and head of Specialty Development at Bristol-Myers Squibb (BMS). Prior to that role, he held the position of senior vice president of Global Pharmacovigilance and Epidemiology. Levy joined BMS in 1997 and during his 17 years at the company, he held a range of senior positions in cardiovascular clinical development, immunoscience clinical research, and global clinical research operations.
Prior to BMS, Levy was a member of the Renal Division at Brigham and Women's Hospital in Boston, Massachusetts, where he was an investigator in federally sponsored outcomes research as well as industry-sponsored clinical trials.
Geoffrey Spolyar focuses his practice on the representation of life sciences companies in a broad range of commercial and financial matters. Much of his practice is devoted to negotiating and drafting corporate partnership agreements, licensing arrangements, strategic alliances, joint venture agreements and other complex technology transactions. Prior to joining Cooley, Geoffrey was senior counsel at Amgen in Thousand Oaks, California where he represented Amgen in a number of strategic alliances including its joint venture with Astellas Pharma in Japan and its collaboration with AstraZeneca regarding several of Amgen’s inflammation programs.